Machine learning of neuroimaging for assisted diagnosis of cognitive impairment and dementia: A systematic review by Pellegrini, Enrico et al.
  
 
 
 
Edinburgh Research Explorer 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Machine learning of neuroimaging for assisted diagnosis of
cognitive impairment and dementia: A systematic review
Citation for published version:
Pellegrini, E, Ballerini, L, Hernandez, MDCV, Chappell, FM, González-castro, V, Anblagan, D, Danso, S,
Maniega, SM, Job, D, Pernet, C, Mair, G, Macgillivray, T, Trucco, E & Wardlaw, J 2018, 'Machine learning
of neuroimaging for assisted diagnosis of cognitive impairment and dementia: A systematic review',
Alzheimer's & Dementia: Diagnosis, Assessment & Disease Monitoring.
https://doi.org/10.1016/j.dadm.2018.07.004
Digital Object Identifier (DOI):
10.1016/j.dadm.2018.07.004
Link:
Link to publication record in Edinburgh Research Explorer
Document Version:
Version created as part of publication process; publisher's layout; not normally made publicly available
Published In:
Alzheimer's & Dementia: Diagnosis, Assessment & Disease Monitoring
General rights
Copyright for the publications made accessible via the Edinburgh Research Explorer is retained by the author(s)
and / or other copyright owners and it is a condition of accessing these publications that users recognise and
abide by the legal requirements associated with these rights.
Take down policy
The University of Edinburgh has made every reasonable effort to ensure that Edinburgh Research Explorer
content complies with UK legislation. If you believe that the public display of this file breaches copyright please
contact openaccess@ed.ac.uk providing details, and we will remove access to the work immediately and
investigate your claim.
Download date: 11. May. 2020
Q13
Q2
Q1
Alzheimer’s & Dementia: Diagnosis, Assessment & Disease Monitoring- (2018) 1-17
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
5455
56
57
58
59
60
61
62Neuroimaging
Machine learning of neuroimaging for assisted diagnosis of cognitive
impairment and dementia: A systematic review63
6465
66
67
68
69
70
71
72
73
74
75Enrico Pellegrinia,1, Lucia Ballerinia, Maria del C. Valdes Hernandeza, Francesca M. Chappella,
Victor Gonzalez-Castrob, Devasuda Anblagana,2, Samuel Dansoa,3, Susana Mu~noz Maniegaa,
Dominic Joba, Cyril Perneta, Grant Maira, Tom MacGillivraya,c, Emanuele Truccod,
Joanna Wardlawa,e,*
aDivision of Neuroimaging, Centre for Clinical Brain Sciences and Edinburgh Imaging, University of Edinburgh, Scotland, UK
bDepartment of Electrical, Systems and Automatics Engineering, Universidad de Leon, Leon, Spain
cVAMPIRE project, University of Edinburgh, Scotland, UK
dVAMPIRE project, Computing, School of Science and Engineering, University of Dundee, Dundee, UK
eUK Dementia Institute, University of Edinburgh, Scotland, UK76
77
78Abstract Introduction: Advancedmachine learningmethodsmight help to identify dementia risk from neuro-Declaration of inte
was conducted in the
that could be construe
1Present Address:
2Present Address:
Trust, UK.
3Present Address:
*Corresponding au
E-mail address: jo
https://doi.org/10.1016
2352-8729/ 2018 Pu
creativecommons.org/
79
80
81
82
83
84
85
86
87
88
89
90
91
92
93
94
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Methods: We systematically reviewed the literature, 2006 to late 2016, for machine learning studies
differentiating healthy aging from aging with dementia of various types, assessing study quality, and
comparing accuracy at different disease boundaries.
Results: Of 111 relevant studies, most assessed Alzheimer’s disease versus healthy controls, using
AD Neuroimaging Initiative data, support vector machines, and only T1-weighted sequences. Accu-
racy was highest for differentiating Alzheimer’s disease from healthy controls and poor for differen-
tiating healthy controls versus mild cognitive impairment versus Alzheimer’s disease or mild
cognitive impairment converters versus nonconverters. Accuracy increased using combined data
types, but not by data source, sample size, or machine learning method.
Discussion: Machine learning does not differentiate clinically relevant disease categories yet. More
diverse data sets, combinations of different types of data, and close clinical integration of machine
learning would help to advance the field.
 2018 Published by Elsevier Inc. on behalf of the Alzheimer’s Association. This is an open access
article under the CC BY license (http://creativecommons.org/licenses/by/4.0/).96
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1091. Introduction
Aging is associated with increasing health-care costs of
which two related neurological disorders, dementia and
stroke, account for much of the increase. The total esti-
mated worldwide cost of dementia was US$818 billion in
2015, representing 1.09% of global GDP Q[1]. In 2015,
46.8 million people worldwide were living with dementia,
a figure which is expected to almost double every 20 years,
reaching 74.7 million in 2030 and 131.5 million by 2050.
Meanwhile, stroke remains the second commonest causesociation. This is an open access article under the CC BY license (http://
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205of death and commonest cause of dependency in adults
worldwide [2].
Age-related cognitive decline ranges from minor reduc-
tions in memory and executive function that do not interfere
with daily life to more severe degrees that fall short of de-
mentia but may interfere with some activities of daily living,
termed “mild cognitive impairment” (MCI). MCI may prog-
ress to dementia or remain static, and cognitive decline is
also a risk factor for stroke.
All three MCI, dementia, and stroke are associated with
changes seen on brain imaging, particularly brain volume
loss (atrophy) and development of focal lesions in the white
and gray matter such as white matter hyperintensities
(WMH), lacunes, microbleeds, focal cortical or subcortical
infarcts, or small hemorrhages. These features are also asso-
ciated with aging (though are less frequent in healthy aging);
may be symptomatic or asymptomatic; and predict increased
risk of stroke, dementia, and death [3].
In the last decade, improvements in medical imaging, expo-
nential increase in computational power of affordable
computing platforms, and greater availability of neuroimaging
data sets, for example, from theAlzheimer’sDisease (AD)Neu-
roimaging Initiative (ADNI), have increased opportunities to
develop machine learning approaches to automate detection,Data set 1
Raw data
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Pre-processed data
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Fig. 1. Workflow of traditional (supervised) machine learning studies. For deep le
preprocessing in some cases) are compressed into a single action (box).
FLA 5.5.0 DTD  DADM268_proofclassification, and quantification of diseases [4]. Machine
learning uses a series of steps to identify, train, and test com-
puter algorithms to identify a feature of interest (Fig. 1).
Some of these techniques have been applied to classify brain
magnetic resonance imaging or computed tomography scans,
comparing patients with dementia and healthy controls, and
to distinguish different types or stages of dementia, cerebrovas-
cular disease, and accelerated features of aging. However, the
recent rapid increase in publications using different machine
learning techniques in different populations, types of images,
and disease criteria make it difficult to obtain an objective
view of the current accuracy of machine learning.
We undertook this systematic review to critically appraise
the accuracy of machine learning to differentiate healthy ag-
ing from MCI from dementia and predict the future risk of
dementia or cerebrovascular disease. We evaluated the per-
formance metrics of individual machine learning techniques
by task, disease of interest, imaging sequence, and features
investigated.2. Methods
We performed the review according to Quality Assess-
ment of studies of Diagnostic Accuracy in SystematicData set 2
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377reviews (QUADAS), a tool designed for the assessment of
published diagnostic studies in systematic reviews, and the
PRISMA guidelines. We registered the protocol of this sys-
tematic review at the international prospective register of
systematic review (PROSPERO, record number:
CRD42016037332).
2.1. Search Strategy
We searched the literature from January 1, 2006 (when
first publications on machine learning in the disorders of in-
terest started appearing in earnest), to September 30, 2016,
on six databases: (1) PubMed/Medline; (2) Elsevier; (3)
IEEE Xplore Digital Library; (4) Science Direct; (5) ACM
Digital Library; and (6) Web of Science.
We devised three groups of keywords, each relevant to
different aspects of the scope of the review:
Brain lesions and relevant pathologies: Dement*, Alz-
heimer, AD, VCI, VaD, small vessel disease, SVD,
microvascular change, cognitive impairment, cognitive
decline, MCI, Lewy bod*, LBD, frontotemporal, FTD,
lacun*, white matter hyperintens*, white matter lesion*,
WMH, leukoaraiosis, periventricular, microbleed*, mi-
crohaemorr*, microhemorr*, stroke, cerebrovascular,
CVA, perivascular space*, PVS, Virchow–Robin space*,
pathological aging, pathological aging, brain, cerebr*,
medial temporal, mesial temporal, volume loss, atrophy.
Machine learning: machine learning, supervised learning,
unsupervised learning, deep learning, classification, iden-
tification, detection, automat* diagnosis, pattern analysis,
CAD, computer-aided diagnosis, computer-assisted diag-
nosis, computational analysis.
Structural imaging: MR, magnetic resonance, structural
imag*, CT, CAT, computed tomograph*.
We searched titles, abstracts, and keyword fields of in-
dexed studies published as journal papers or conference
proceedings, with all possible strings obtained by joining
one term from each of the aforementioned groups with an
“AND” operator. One reviewer (E.P.) conducted the
searches and eliminated all duplicate references.
2.2. Inclusion/exclusion criteria
Two reviewers (E.P. and V.G.C.) separately assessed all
nonduplicate papers in a two-stage selection process. First,
we evaluated titles and abstracts to exclude studies clearly
not relevant to the scope of the review. Second, we assessed
full texts of the remaining papers to eliminate studies using
the following exclusion criteria:
1. Studies of animals or ex-vivo samples.
2. Reviews, surveys, collections, and comparison pa-
pers not presenting a newML method or application.
3. Studieswith a validation set comprising a small number
of subjects (,100 for disease classification or lesion
identification tasks and ,25 for pixel- or voxel-levelFLA 5.5.0 DTD  DADM268_prooflesion segmentation tasks) or with a manual ground
truth provided by only one trained observer.
4. Studies presenting a method in which the main task
(e.g., lesion segmentation) was not performed in a
fully automated fashion. Studies involving semiauto-
mated preprocessing steps (e.g., brain parcellation
refinement) obtained by making use of previously
validated software and trained observers were
accepted.
5. Studies not about structural magnetic resonance im-
aging or computed tomography imaging.
6. Studies focused on image preprocessing techniques
that did not include any machine learning for disease
classification or lesion segmentation/identification
(e.g., contrast enhancement, noise reduction tech-
niques, and so forth).
7. Studies of parcellation of healthy brain regions not
used for disease classification or detection.
8. Studies that either did not provide or presented their
results in such a way that we were not able to calcu-
late performance metrics (e.g., sensitivity and speci-
ficity).
9. Multiple publications from the same research group,
focusing on the same task and data set. In such cases,
only the most recent publication or that with the
largest sample size was included in the data analysis.
10. Studies that did not describe their methods in suffi-
cient detail to enable replication.
Discrepancies were resolved by discussion between the
two reviewers with a third (M.V.H., L.B., and G.M.) arbi-
trating as necessary. Notice that none of the studies satis-
fying the abovementioned criteria reported testing on
training data (i.e., either independent training and data sets
or proper cross-validation were used); hence, this otherwise
necessary exclusion criterion is not included.2.3. Data extraction
From the included papers, we extracted data on the
following:
1. disease or lesion investigated,
2. data set used and whether it was publicly available or
not,
3. number of subjects or images on which the proposed
technique had been validated,
4. type of structural imaging modality and sequences
used,
5. imaging features that were investigated,
6. use of any additional imaging data (e.g., functional
imaging) or nonimaging features (e.g., cognitive test
scores) in the analysis,
7. classifier(s) and the feature selection and representa-
tion techniques used, and
8. performance (sensitivity, specificity, and accuracy) of
the proposed method. 10 August 2018  4:10 pm  ce
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463We extracted data to calculate sensitivity and specificity
where they are not already calculated.
If multiple tasks were investigated in a single study, the
respective data for each experiment were recorded.
We also extracted (when reported) details of use of single
versus multiple scanners, image resolution, population de-
mographics, exclusion criteria for each dataset, image pre-
processing steps, time cost, and use of third-party software
(details available on request).
We evaluated study quality according to the relevant
QUADAS-2 criteria (https://www.ncbi.nlm.nih.gov/pubmed/
22007046).We used the seven criteria that were most relevant
to the material of the review, four addressing risk of bias and
three addressing applicability, because some criteria were not
strictly applicable to the field. All acronyms are reported in
Supplementary Table 1464
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5112.4. Data analysis
We extracted the different performance metrics directly
from the papers or calculated them from the data provided.
In particular, we aimed to examine the following:
1. Sensitivity, specificity, and accuracy for binary classi-
fication tasks.
2. Mean class accuracy for multiclass classification
tasks.
3. Dice coefficient for accuracy of lesion segmentation
tasks.
4. Precision and recall for lesion identification tasks
(calculated using the formula in Supplementary
methods).
Where the results of multiple experiments for the same
classification task were reported in a single study, we only
used the set of metrics associated with the higher value of ac-
curacy in our analysis.
We constructed forest plots to summarize sensitivity,
specificity, accuracy, and 95%confidence intervals of various
clinically relevant diagnoses including AD versus healthy
aging,MCI versus AD or healthy aging, andMCI conversion
toADversus not conversion. To summarize themass of infor-
mation effectively, we plotted forest plots of accuracy rather
than sensitivity and specificity, which is defined as:
Accuracy5 ðTP1TNÞ=ðTP1FN1FP1TNÞ
We performed sensitivity analyses to determine if source
data set, machine learning method, type of data used, or
study size accounted for the variance between studies. We
calculated 95% confidence interval of accuracy using the
Wilson [4] score method. We plotted all graphs in R. We
considered but rejected performing a formal meta-analysis
because the huge overlap in data sets in publications pre-
cluded determining the results of patients who contributed
to more than one study (even with exclusion of obvious
duplicate publications), preventing the modeling ofFLA 5.5.0 DTD  DADM268_proofbetween-study variance. Finally, to minimize confounding
by inclusion of studies that only contributed to one compar-
ison, we compared accuracy across multiple diagnostic
boundaries using studies that provided data on more than
one diagnostic comparison from the same data set.2.5. Role of the Funding Source
The funders had no role in the conduct of this systematic
review. The corresponding author confirms that she had full
access to all the data in the study and had final responsibility
for the decision to submit for publication.3. Results
Our search yielded 5775 nonduplicate studies, of which
4978 (86%) were excluded at title/abstract screening as
clearly not relevant to the review. After full-text screening,
we found 111 papers relevant for data extraction (Fig. 2).
The two criteria accounting for the most exclusions were
small sample (item 3) and no performance metrics provided
or calculable (item 8; 41% and 19% of exclusions at this
stage, respectively; for proportions meeting exclusion
criteria see Supplementary Table 2). Note that studies that
failed one exclusion criterion were excluded and not evalu-
ated further; although some might have failed on multiple
criteria, we only recorded the first reason for exclusion.
Most of the 111 studies that met inclusion criteria
achieved low risk of bias scores and low concerns on appli-
cability (Supplementary Table 3; Supplementary Fig. 1). Of
the 111, we used 89 studies in further analyses of accuracy
where data could be extracted as 2 ! 2 tables, and there
were sufficient studies to compare.
Most studies tested the diagnosis of AD (68/89, 76%),
most versus healthy controls (67/89, 75%), then MCI non-
converters to AD versus converters to AD (37/89, 42%),
MCI versus healthy controls (29/89, 33%), and MCI versus
AD (8/89, 9%; Table 1 shows individual comparisons; full
details are provided in Supplementary Table S3). There
were 21 studies that compared multiple diagnostic classes,
ofwhichmany involved the same author groups.Most studies
used structural imaging, although some included other imag-
ing such as diffusion tensor or radioisotope methods (details
provided in Supplementary Table 3); however, therewere too
few such studies and incomplete reporting of accuracy by im-
aging type to analyze these additional imaging types.
The remaining studies focused on other factors, other
types of dementia (five studies; Supplementary Table S4),
and studies investigating different types of brain lesions
related to dementia, stroke, and pathological aging, either
lesion segmentation (seven studies; Supplementary Table
S5) or lesion identification (11 studies; Supplementary
Table S6). As there were few eligible studies in the latter
three categories, it was not possible to undertake any formal
comparisons, for example, of DICE coefficients (for WMH,
ischemic stroke lesions), precision, or recall values (for 10 August 2018  4:10 pm  ce
Fig. 2. Flowchart of search and exclusion stages of the review.
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645microbleeds, lacunes). However, the DICE coefficients for
WMH segmentation (four studies, mean n 5 81, range,
38–125) ranged from 0.520 to 0.691 and for infarcts (three
studies, mean n 5 42, range, 30–60) ranged from 0.670 to
0.740 (Supplementary Table S5). The precision/recall values
for microbleeds (three studies, mean n 5 66, range, 50–81)
for precision ranged 0.101 to 0.443 and for recall they were
between 0.870 and 0.986; there was one study on lacunes
(n 5 132) with precision of 0.154 and recall of 0.968
(Supplementary Table S6).
The 76 analyses focused on AD (Supplementary Table
S3) amounted to 68 unique references, with huge overlap
in authors and data sources between the studies. As using
more than one data source, many studies performed more
than one comparison of disease classifications with these
multiple data sources, hence amounting to 144 different
comparisons (Table 1). Of the 144 comparisons, there
were 120 uses of ADNI data (ADNI alone 119/144, 83%;
ADNI plus other 120/144, 83%), followed by Oasis (10/
144, 7%), local sources (7/144, 5%), and AddNeuroMed
(alone 3/144, 2%; plus ADNI 4/144, 3%).
The 76 analyses of AD tested nine different machine
learning methods. The most frequent, by a large margin,
was support vector machine with 46/76 (61%) when alone
and 53/76(70%) when combined with another machine
learning method, followed by linear discriminant analysis
(6/76, 8%), logistic regression (4/76, 5%), and a few testing
k-nearest neighbors such as orthogonal projections to latent
structures, random forest, or sparse representation classifica-
tion (Table 1). Most analyses, by a large margin, used only
T1 images (91/144, 63%), with modest numbers using T1FLA 5.5.0 DTD  DADM268_proofplus other sequences, other types of data, or both. Analysis
sample sizes ranged from 100 to 902, with similar numbers
of analyses including more than 300 subjects (51/144, 35%)
or fewer than 150 subjects (45/144, 31%) (Table 1).
Among the 76 studies focused on AD, the accuracy was
higher for differentiatingAD fromhealthy controls (most study
accuracies were in the 0.8–1.0 range) than for differentiating
MCI fromhealthy controls (accuracies5 0.6–0.9), nonconvert-
ing from converting MCI to AD (accuracies 5 0.5–0.85), or
MCI from AD (accuracies 5 0.6–0.9). Fig. 3A–D indicates
the lower accuracy for differentiating healthy controls from
MCI, MCI from AD, or MCI nonconverters from converters
than healthy controls fromAD; Supplementary Figs. 2–4 illus-
trate these same comparisons ordered by data source, machine
learning method, and study size, respectively. There was little
evidence of any difference in accuracy by machine learning
method, data source used, or study size,with possible higher ac-
curacy for combinedT1 plus other sequences and other types of
data than for T1 imaging alone.
Finally, restricting comparisons of accuracy to studies
that examined more than one diagnostic classification
(Fig. 4A–D) demonstrates the lower accuracy for differenti-
ating between healthy controls and MCI, MCI from AD, or
either healthy controls or AD and MCI converting/noncon-
verting from healthy controls or AD (Fig. 4A–D).4. Discussion
We found acceptable accuracy for all machine learning
methods in differentiating healthy controls from AD but
fewer data and lower accuracies for differentiating healthy 10 August 2018  4:10 pm  ce
Table 1
Number of comparisons in each systematic review analysis group using specified data source, machine learning method, types of imaging and nonimaging data,
and by study size
Data sources HC versus AD HC versus MCI MCInc versus MCIc MCI versus AD Total
ADNI 54 24 34 7 119
ADNI 1 Bdx-3C 0 0 1 0 1
AddNeuroMed 1 0 2 0 3
AddNeuroMed 1 ADNI 2 1 1 0 4
Local 4 3 0 0 7
OASIS 7 2 0 1 10
Total 68* 30 38 8 144
Machine learning method
AdaBoost 1 0 1 0 2
Deep Learning 2 2 0 0 4
Gaussian process 0 0 1 0 1
LDA 5 0 5 1 11
Logistic regression 4 0 2 0 6
OPLS 2 1 1 0 4
QDA 0 0 1 0 1
RBF-NN 0 0 1 0 1
Random forest 3 1 3 0 7
SRC 2 1 2 0 5
SVM 39 22 17 7 85
SVM 1 MKL 3 1 1 0 5
SVM 1 OPLS 1 0 1 0 2
SVM 1 random forest 2 1 2 0 5
SVM 1 SRC 1 1 0 0 2
kNN 3 0 0 0 3
Total 68* 30 38 8 144
Types of imaging and imaging plus
nonimaging data used
T1w only 46 13 26 6 91
T1w and other imaging data 8 8 2 0 18
T1w and other types of data 8 3 8 1 20
T1w and both other imaging and types of
data
6 6 2 1 15
Total 68* 30 38 8 144
Size of data set (range from 100 to 902
participants)
150 and under 30 4 9 2 45
151 to 200 4 10 6 0 20
201 to 250 9 4 6 0 19
251 to 300 4 2 3 0 9
Over 300 21 10 14 6 51
Total 68* 30 38 8 144
Abbreviations: HC, healthy control; AD, Alzheimer’s disease; MCI, mild cognitive impairment; nc, nonconverter to AD; c, converter to AD; LDA, linear
discriminant analysis; KNN, k-nearest neighbors; OPLS, Orthogonal Projections to Latent Structures; SRC, Sparse Representation Classification.
NOTE. Individual studies contribute to more than one analysis and use more than one data source, machine learning method, combinations of imaging data,
and more than one data set (hence more than one sample size in some studies).
*In the 68 HC versus AD comparisons, one study is counted twice as it used two different kinds of imaging.
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779controls from MCI, or MCI from AD, or (more concerning)
for risk prediction of MCI nonconverters from converters to
AD. From a clinical perspective, the comparison of healthy
controls to AD is the least important distinction; such type I
diagnostic studies do not produce clinically relevant esti-
mates of sensitivity and specificity but test the initial feasi-
bility of a method. Although the results for machine
learning methods in differentiating healthy controls from
AD are encouraging, the performance across the other
cognitive diagnosis categories indicates that the field has
some way to go before these methods should enter routineFLA 5.5.0 DTD  DADM268_proofclinical use [5]. The over-reliance on one data source, popu-
lations skewed to the disease of interest with small propor-
tions of controls, one type of imaging, and one machine
learning method further limits the clinical relevance and
generalizability of the results. This may reflect that, as yet,
machine learning is still insufficiently intertwined with the
clinical world, in part due to misalignment of targets and
methods; although the machine learning community aims
primarily for algorithm novelty, inspired largely by com-
puter vision and machine learning, clinicians want reliable,
validated methods for early diagnosis, risk prediction, or 10 August 2018  4:10 pm  ce
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Fig. 3. Differentiation of (A) healthy controls from AD, (B) HC fromMCI, (C) MCI converters from nonconverters, and (D) MCI from AD, ordered according
to the type of data used: T1W Q11only, T1W 1 other sequences, T1W 1 nonimaging data, and T1W 1 other sequences 1 nonimaging data. Abbreviations: AD,
Alzheimer’s disease; HC 5 healthy control; MCI, mild cognitive impairment.
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methods, and change clinical practice.
We aimed to include as many relevant papers as
possible, so kept the search broad. We retained conference
papers (where sufficient data were reported) to reflect theFLA 5.5.0 DTD  DADM268_prooftendency to publish conference papers that equate to full
publications in the fast-moving medical image analysis,
computer vision, and machine learning fields. High-
quality conferences are at least as selective as many jour-
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included papers were conference papers. The number of
unrefereed preprints becoming available online (e.g., ar-
Xiv, biorXiv) is also increasing rapidly, but we did notFLA 5.5.0 DTD  DADM268_proofinclude these preprint publications because they are not
peer-reviewed. However, the use of these sites for dissem-
ination is growing and may need considering in future re-
views. The proportion of papers using deep learning has
increased since late 2016 (including several published by 10 August 2018  4:10 pm  ce
w
e
b
4
C
=
F
P
O
w
e
b
4
C
=
F
P
O
Fig. 3. (continued).
E. Pellegrini et al. / Alzheimer’s & Dementia: Diagnosis, Assessment & Disease Monitoring- (2018) 1-17 9
1048
1049
1050
1051
1052
1053
1054
1055
1056
1057
1058
1059
1060
1061
1062
1063
1064
1065
1066
1067
1068
1069
1070
1071
1072
1073
1074
1075
1076
1077
1078
1079
1080
1081
1082
1083
1084
1085
1086
1087
1088
1089
1090
1091
1092
1093
1094
1095
1096
1097
1098
1099
1100
1101
1102
1103
1104
1105
1106
1107
1108
1109
1110
1111
1112
1113
1114
1115
1116
1117
1118
1119
1120
1121
1122
1123
1124
1125
1126
1127
1128
1129
1130
1131
1132
1133
1134
1135
1136
1137
1138
1139
1140
1141
1142
1143
1144
1145
1146
1147
1148
1149
1150
1151
1152
1153
1154
1155
1156
1157
1158
1159
1160
1161
1162
1163
1164
1165
1166
1167
1168
1169
1170
1171
1172
1173
1174
1175
1176
1177
1178
1179
1180
1181the authors, many conference papers in MIUA2018 and
MICCAI2017), and therefore, this review may under-
represent the most recent developments in machine
learning. However, although a brief update of our search
to June 2018 found about 100 more papers, most were
from the same research groups, published in conference
proceedings or ArXiv preprints (therefore would not meetFLA 5.5.0 DTD  DADM268_proofour inclusion criteria), which revealed a substantial expan-
sion in deep learning methods but no obvious shift in accu-
racy or reporting standards. Many of these recent papers
still focused on methods to detect single brain lesion types,
such as WMH or atrophy, that are associated with cognitive
decline (but not with degrees of cognitive decline itself) or
with differentiating AD from healthy controls rather than 10 August 2018  4:10 pm  ce
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the present analysis, based on a substantial body of work to
late 2016, would change by the inclusion of these most
recent papers.
Some nonsystematic reviews and surveys on machine
learning have been published [6–12]. Our work included
more recent papers, assessed more outcomes, and included
sensitivity analyses to assess the impact of key study andFLA 5.5.0 DTD  DADM268_proofpopulation characteristics than prior reviews [13–15],
Applications of deep learning not only in brain but, more
in general, in medical imaging have been reviewed in a
recently published survey [16]. This work differs from
ours in terms of methods (it is not a systematic review)
and focus (we did not limit our analysis to deep learning)
and scope (we did not include preprints and non–peer-re-
viewed publications because they lack detail). 10 August 2018  4:10 pm  ce
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Fig. 4. Studies which included more than one diagnostic classification. (A) Healthy controls versus MCI and healthy controls versus AD. (B) Healthy controls
versus MCI converting and MCI converting versus MCI nonconverting. (C) MCI converting versus MCI nonconverting and MCI versus AD. (D) Healthy con-
trols versus AD and MCI versus AD. Abbreviations: AD, Alzheimer’s disease; MCI, mild cognitive impairment.
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by including more small studies and also believe that theFLA 5.5.0 DTD  DADM268_proofmain messages embedded in the current literature are
captured well by the review.
We excludedmore than 200 papers (Supplementary Table
S2) because the sample size or ground truth annotations were
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(achieving the best values for specific performance parame-
ters), more than maximizing the amount of data made avail-FLA 5.5.0 DTD  DADM268_proofable, the generalizability of the results, or relevance to
clinical practice. The latter two should receive more atten-
tion if the field is to advance.
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1985software for data and image analysis [17–19]. Some aspects of
the perceived importance of standard criteria and data sets are
highlighted by the clear majority of papers using the ADNI
data set (www.adni-info.org). Although use of one data set
may promote cross-comparisons of results, it is likely to inflate
estimates of accuracy and considerably reduces the generaliz-
ability of the results to clinical practice. Deep learning tech-
niques are rapidly becoming the methods of choice in
medical image analysis and feature in increasing proportions
in conferences and journals, for example, many conference pa-
pers at MIUA2017. However, the overall message remains the
same, i.e., differentiation of AD from healthy controls, but
fewer studies and poorer accuracy at differentiating MCI
versus healthy control or AD, orMCI converters/nonconverters
to AD, with the same problems of sample size, repeated use of
the same data and lack of clinical integration. This further in-
creases the need for large data sets as convolutional neural net-
works havemillions of parameters to train. The performance of
systems classifying brain images as associated with AD or not
seems to improve when using multiple data types [20, 21].
Including nonimaging features, such as CSF biomarkers and
cognitive test scores, unsurprisingly also improve
performance. Further work is needed to clarify the interplay
between data from images and other sources [22].
Most studies started with preprocessed features (“ground
truth”) as input to the machine learning method. Many pre-
processing techniques used population templates that derive
from young populations; these are of limited relevance to the
older brain and may bias the resulting outputs [22]. Very few
papers on lesion segmentation techniques were included as
most failed the inclusion criteria on annotations (ground
truth). This reflects that generating sufficient ground truth
for a reliable validation of such algorithms is time
consuming and highlights a limitation of machine learning
methods in relying on ground truth. Use of crowd-sourcing
to annotate images may be one solution but would have to
achieve high reliability to meet the definition of “ground
truth” [23–25]; their use remains subjudice and depends
on the application. We also notice recent work on
automatic generation of annotations (auto-annotations) for
nonymedical classifiers with large numbers of classes
[26] and growing interest of medical image analysts in tech-
niques to minimize the number of annotations required
without affecting performance [27].
It proved particularly difficult to locate papers attempting
stratification of different types of dementia, and few studies
combined imaging with other data types. Possible reasons
include that diagnosing dementia is not a clear-cut process,
so several covariates should be considered in addition to a bi-
nary dementia/no dementia, for example, time of diagnosis,
source data for diagnosis (MCI test, brain images, clinical
records, prescriptions) while avoiding inappropriate circu-
larity by including variables such as current cognitive test re-
sults (several papers may have inflated their estimates of
accuracy by including current cognitive test results in their
algorithm (Supplementary Table 3) but were too few in num-FLA 5.5.0 DTD  DADM268_proofber to test the effect in sensitivity analyses. Different demen-
tia components might be present at the same time. Finally, to
our best knowledge, no reliably stratified, sufficiently large
public neuroimaging data sets exist.
Practically all the included papers werewritten for a com-
puter science or engineering audience. They focused on
technical information (e.g., algorithm, parameter setting,
training protocol) omitting essential clinically relevant in-
formation (e.g., patient demographics, clinical covariates,
data acquisition protocols). To elaborate further, practically
all the papers included were written for a computer science
or engineering audience. A consequent, but serious, limita-
tion for effective interdisciplinarity is that a clinical audience
does not appreciate easily the potential, value, and limits of
the methods presented; most technical papers do not address,
for instance, issues of patient demographics, disease cate-
gory, clinical covariates, or data acquisition protocols, which
are important for clinicians.
Specialized journals and conferences require specialist lan-
guage, but international efforts are needed to make technical
papers more understandable to a clinical audience, and vice
versa, for example, clinician-oriented summaries addressing
the points above, and more.5. Conclusions
Our review indicates that machine learning methods to
predict risk of dementia are not yet ready for routine use.
Better interdisciplinary collaborations and internationally
agreed (by clinicians and computer science/engineers) vali-
dation protocols and clinical trials are needed. Development
of more machine learning methods in neuroimaging requires
much greater interdisciplinary working, varied and clinically
relevant annotated data sets, varied imaging types not just
T1, and focus on relevant outcomes to ensure that the result-
ing machine learning methods are robust and reliable before
testing in clinical trials.Acknowledgments
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